Subsequent adjuvant chemotherapy to eradicate residual systemic disease [24] showed that chemotherapy and/or hormonal therapy is effective in the management of women with estrogen-receptor (ER)-negative or ER-positive tumours. The gene discussed is ESR1; the disease is neoplasm.